Celltrion discloses preliminary third-quarter operating profit of 510 billion won

Celltrion disclosed preliminary consolidated results for this year's third quarter on the 12th. Revenue was 1.5 trillion won and operating profit was 510 billion won, up 45.8% and 69.2%, respectively, from a year earlier; its operating margin rose 4.7 percentage points to 34%.

Celltrion exceeded the quarterly operating profit targets it set at the start of the year for three consecutive quarters. The targets were at least 300 billion won for the first quarter, 400 billion won for the second and 500 billion won for the third.

In the United States, Steqeyma had a 15% market share and Yuflyma an 11% share as of August. Existing products Truxima and Inflectra had shares of 39% and 31%, respectively.

Celltrion intends to expand sales of follow-on products and continue improving costs. The company said it plans to use these efforts to maintain growth in the fourth quarter and focus on meeting its annual business plan.